MAIA Biotechnology (MAIA) Return on Capital Employed (2022 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Return on Capital Employed of 159.31% for Q1 2026, up 15037.0% year-over-year from N/an in Q1 2025, and up 67.79% quarter-over-quarter from 494.6% in Q4 2025.
MAIA Biotechnology (MAIA) Return on Capital Employed (2022 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Return on Capital Employed for 5 consecutive years, with 159.31% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 15037.0% year-over-year to 159.31%; the TTM figure through Mar 2026 stood at 159.31% (up 15037.0% YoY), while the FY2025 annual figure was 592.87%, down 25582.0% from the prior year.
- Return on Capital Employed climbed to 159.31% in Q1 2026 per MAIA's latest filing, from 494.6% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 152.63% in Q3 2022 and bottomed at 1758.16% in Q3 2025.
- Historically, Return on Capital Employed has averaged 438.81% across 5 years, with a median of 288.93% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed surged 57106 bps — and 2025, when it slumped 149713 bps.
- MAIA Biotechnology's Return on Capital Employed stood at 159.63% in 2022, then plunged by 439 bps to 859.99% in 2023, then surged by 66 bps to 288.93% in 2024, then sank by 71 bps to 494.6% in 2025, then soared by 68 bps to 159.31% in 2026.
- Business Quant data shows MAIA's Return on Capital Employed at 159.31% in Q1 2026, 494.6% in Q4 2025, and 1758.16% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | -113.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -113.41% |
| Mar 31, 2026 | -159.31% |
| Dec 31, 2025 | -494.60% |
| Sep 30, 2025 | -1,758.16% |
| Jun 30, 2025 | -308.59% |
| Mar 31, 2025 | -309.68% |
| Dec 31, 2024 | -288.93% |
| Sep 30, 2024 | -261.03% |
| Jun 30, 2024 | -278.52% |
| Mar 31, 2024 | -616.85% |
| Dec 31, 2023 | -859.99% |
| Sep 30, 2023 | -401.33% |
| Jun 30, 2023 | -283.49% |
| Mar 31, 2023 | -249.45% |
| Dec 31, 2022 | -159.63% |
| Sep 30, 2022 | -152.63% |